New insights toward personalized therapies for vulvovaginal candidiasis and vaginal co-infections

View Full Paper

Ask AI

Bookmark

Personalized therapies significantly improve outcomes for vulvovaginal candidiasis and bacterial vaginosis, focusing on the vaginal ecosystem.
Antifungal drug resistance presents challenges in treatment, affecting women's health and the effectiveness of existing therapies.
The review discusses the role of Lactobacillus in maintaining the vaginal microbiota, linking it to health outcomes and resilience against infections.
Future approaches propose targeting host factors and microbiota to develop treatments that prevent reinfection and minimize adverse effects.

Discussion

No takes yet. Share an insight, caveat, or question.

This review explores treatments for vulvovaginal candidiasis and bacterial vaginosis, highlighting the role of microbiota in persistent infections.

Seta et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This review explores treatments for vulvovaginal candidiasis and bacterial vaginosis, highlighting the role of microbiota in persistent infections.